Multidrug-resistant Pseudomonas aeruginosa (MDRPA) is one of WHO’s top three pathogens for which drugs are critically needed. In patients with MDRPA infection, resistance to widely used antibiotics, such as anti-pseudomonal beta-lactams or quinolones, has led to the use of alternative treatment, such as colistin or aminoglycosides, which confer a high risk of nephrotoxicity. Now, the researchers have come up with an alternative therapy for effective management of MDRPA infections. The combination of ceftolozane/tazobactam (C/T) has been found to be highly effective against MDRPA.
In particular, ceftolozane is very stable to common resistance mechanisms in P. aeruginosa that compromise some of older beta-lactam options. In the study, the researchers studied isolates from 276 patients with MDRPA infections. Susceptibility rates of the MDR aeruginosa isolates to four different antibiotic…
